Indolium 1 Exerts Activity against Vemurafenib-Resistant Melanoma In Vivo

The development of targeted therapies (BRAF/MEK inhibitors) and immunotherapy have had a major impact on the treatment of melanoma. However, the majority of patients with advanced melanomas succumb to their disease. The mechanisms of resistance to both targeted therapies and immunotherapies are nume...

Descripción completa

Detalles Bibliográficos
Autores principales: Radi, Rakan, Huang, Christina, Elsey, Justin, Jung, Yoon H., Corces, Victor G., Arbiser, Jack L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137681/
https://www.ncbi.nlm.nih.gov/pubmed/35624662
http://dx.doi.org/10.3390/antiox11050798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137681/
https://www.ncbi.nlm.nih.gov/pubmed/35624662
http://dx.doi.org/10.3390/antiox11050798

Ejemplares similares